Last Updated on October 6, 2024 by The Health Master
Drug Approval
In the dynamic landscape of pharmaceuticals, speed is often the key to innovation with respect to drug approval.
The Organisation of Pharmaceutical Producers of India (OPPI), representing major multinational pharma companies, has recently raised a crucial concern.
The organization is urging the Drug Controller General India (DCGI) to facilitate parallel drug approval in India, aligning with global markets.
This move aims to overcome the significant delay in launching new medicines in India compared to the US and the European Union.
Understanding the Delay
Complex Clinical Trial Regulations
Launching a new drug in India is a time-consuming process, with delays stretching up to four years.
The OPPI attributes this setback to the intricate web of clinical trial regulations.
These regulations, while essential for ensuring the safety and efficacy of drugs, inadvertently hinder the timely introduction of innovative and vital pharmaceutical products in the Indian market.
OPPI’s Vision for Transformation
Advocating for Parallel Filing
The OPPI envisions a transformative approach to streamline drug approval processes.
It advocates for regulations that permit the parallel filing of marketing approval applications, synchronizing with major global markets.
In a recent statement, the pharma lobby group expressed its vision, stating, “OPPI envisions a transformative approach to drug approval processes, advocating for regulations that enable parallel filing of marketing approval applications in sync with major global markets.”
Collaborative Efforts with Regulatory Agencies
Dialogue with the Drug Controller General of India (DCGI)
Acknowledging the challenges surrounding global clinical trials, the DCGI engaged in a dialogue with both domestic pharma lobby groups and foreign players.
The OPPI emphasized the importance of establishing a predictable regulatory pathway with minimal ambiguity. The ultimate goal is to enable early access to innovative therapies for patients in India.
Reducing Time Lag through Global Studies
Actively Participating in Global Studies
The OPPI, representing pharma giants like Novartis, Roche, AstraZeneca, Sanofi, and Merck, aims to drastically reduce the time lag of approximately 18 months, which sometimes extends to 3-4 years.
This delay occurs when bringing innovative therapies to Indian patients compared to the launch dates in the US or the EU.
The strategy involves active participation in global studies and pursuing parallel Marketing Authorisation filings.
Catalyzing a Paradigm Shift
Positioning India as a Proactive Player
The OPPI’s recommendations not only seek to expedite patient access to innovative medicines but also aim to position India as a proactive player in global clinical trials.
By catalyzing a paradigm shift, the organization aspires to make India a preferred destination for phase-III studies and global clinical trials.
This, in turn, would pave the way for a more agile and patient-centric healthcare landscape.
OPPI’s Presentation to the DCGI
Timelines and Recommendations
In a presentation to the DCGI, the OPPI outlined how timelines could be significantly shortened to less than two years.
This could be achieved by India’s active participation in global trials, ensuring early access to innovation in the country.
Furthermore, the organization suggested that the overall review timelines could be reduced to 12 months or conducted in parallel with the US and the EU.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
National Human Rights Commission’s Inquiry into Medicines Standards
India’s First Child-Friendly Chemotherapy Drug Developed
USFDA approval granted for Posaconazole Injection
NPPA Recommends Retail Prices for Anti Diabetes Drug Combinations
USFDA approval granted for Loteprednol Etabonate Ophthalmic Suspension
Income Tax demand notice for Rs 284.58 Cr to Zydus Lifesciences arm
Risks of OTC Cough Syrup for Children Below 4 Years
HPMA’s Plea for Industry Relief
USFDA Approvals in the year 2023: A Snapshot
Govt approved 746 applications till November under PLI Schemes
